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Introduction
In the first decade of the 21st century, reported 30-day mortality following stroke varied between 13% and 23% after ischemic stroke, and between 25% and 48% after intracerebral or subarachnoid hemorrhage [1] . Recent reports on 5-year mortality range between 40% and 61%, depending on stroke type [2, 3] . Improvements in stroke care and stringent control of vascular factors have reduced post-stroke mortality [2] [3] [4] , but as of 2015 stroke remained a leading cause of death [5] . The continuing application of evidence-based public health programs and clinical interventions is essential to reduce post-stroke mortality further [4] .
During 1994-2011, approximately 40% of stroke patients in Denmark had major comorbidities at diagnosis, and this proportion has increased in recent years [3] . Comorbidity affects both short- [3, 6, 7] and long-term [2, 3] mortality after hospital admission for stroke. However, it is unknown whether comorbidity leads to excess post-stroke mortality, that is mortality beyond that expected from combined individual effects of stroke and comorbidity. During the acute period, comorbidity could contribute to excess post-stroke mortality by contraindicating or delaying standard therapy. Later, interaction between comorbidity and stroke could directly or indirectly affect excess mortality by increasing patient disability [8, 9] , by increasing the risk of bleeding or thrombosis [10] , or by inducing other stroke complications [11] or stroke recurrence [12] . Understanding the magnitude of excess mortality due to interaction with comorbidity may thus help postpone post-stroke mortality through tailoring interventions according to comorbidity.
Using nationwide databases covering all Danish hospitals, we conducted a cohort study (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) to examine the interaction between stroke and comorbidity affecting all-cause mortality among adults. We assessed interaction as a measure of the surplus, or excess mortality rate not explained by the combined effects of stroke and comorbidity acting individually.
Methods

Setting and databases
Denmark provides all its residents with access to tax-supported healthcare. The Danish National Health System stores extensive healthcare information using registry databases [13] . Data sources have been linkable at the individual level since 1968, by means of unique identifiers assigned by the Civil Registration System (CRS) [14] . The CRS also maintains up-to-date information on the vital and migration status of the entire population, enabling complete follow-up.
It is medical practice in Denmark to manage acute stroke patients in inpatient settings [15] . The Danish National Patient Registry (DNPR) has recorded > 99% of inpatient admissions since 1977 and outpatient clinic visits since 1995. The DNPR contains information on the dates of inpatient admission and discharge, outpatient visit date, the diagnosis leading to hospital contact, and up to 20 additional diagnoses coded according to the International Classification of Diseases, Eighth Revision until 1993 and Tenth Revision thereafter. Since 1999, the DNPR has information on the presence of structural brain imaging (computed tomography or magnetic resonance imaging) performed during hospitalization for stroke [16] . After 2003, brain-imaging procedures for stroke patients became widely implemented in Denmark, allowing for a high level of completeness of specific stroke diagnoses recorded in the DNPR [17, 18] .
Stroke cohort
Based on information in the DNPR, we identified all patients ≥ 18 years old with incident ischemic stroke, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and unspecified stroke diagnosed in inpatient settings during 1995-2012. Compared with medical records, the positive predictive value of a first-time inpatient diagnosis of stroke in the DNPR is 81% to 86% [16] . We accessed DNPR records starting in 1977 to exclude patients with any preexisting diagnoses of stroke, other cerebrovascular disease or hemiplegia (as an indicator of earlier stroke), as of the date of stroke diagnosis (defined as the index date).
Comorbidity
For each patient, we used the hospital inpatient discharge and outpatient visit records in the DNPR to identify all 19 diseases included in the Charlson Comorbidity Index (CCI) [19] , except for cerebrovascular disease and hemiplegia. The CCI has been shown to validly discriminate neurological disability and subsequent mortality after stroke [6] . Compared with medical records, the positive predictive value of the CCI comorbidities in the DNPR is 98% [20] . Each CCI disease is assigned a severity-weight score between 1 and 6 based on its adjusted association with 1-year mortality [19, 20] . In this study, we assessed each CCI disease both individually and as a component of a summed CCI score. We defined patient comorbidity levels according to the summed CCI score as 0 (no comorbidity), 1 (low comorbidity), 2-3 (moderate comorbidity) and 4+ (high comorbidity).
General population comparison cohort
We constructed a comparison cohort from the general population using the CRS and the DNPR. For each stroke patient, we identified up to five individuals in the population with no preexisting diagnoses of stroke, other cerebrovascular disease or hemiplegia. Each comparison cohort member was matched to a stroke patient, without replacement, by sex, year of birth (in 5-year intervals) and history of individual CCI comorbidities diagnosed within 10 years before the index date. We chose this 10-year period to capture most clinically relevant comorbidities, and to avoid that patients with more time in the DNPR would have more opportunity to be identified as having a comorbidity than those with less time [21] .
Mortality
We identified the outcome of all-cause mortality using the CRS. We followed individuals from their index dates until the earliest of death, emigration, 30 November 2013 or 5 years of follow-up.
Statistical analysis
For the combined stroke cohort and for the ischemic and hemorrhagic (ICH or SAH) stroke cohorts, we computed 30-day and 5-year mortality risks using the Kaplan-Meier method. We also computed mortality rates and rate differences. When calculating the rates, we stratified person-time into three periods: 0-30 days, 31-365 days and > 1-5 years of follow-up. The analyses for the 31-365 days and > 1-5 years of follow-up included only the 30-day and the 12-month survivors after the index date, respectively. We reported 30-day rates per person-months and rates per person-years for the subsequent follow-up. Because we expected the cohorts to have differing age and sex characteristics at the start of different follow-up periods, we dissolved the matching and standardized the rates to the age and sex distribution of members of the stroke cohort as of their index dates.
Using standardized mortality rates, we assessed the interaction contrast (IC) as the excess mortality in patients with both stroke and comorbidity, beyond that expected by their independent additive effects [22] . We calculated the interaction contrast by subtracting the mortality rate difference following stroke (compared with the rate difference in the general population) in individuals with comorbidity from that of individuals without comorbidity, as:
where Rate stroke 1 jCCI ! 1 represents the mortality rate in the stroke cohort with comorbidity, Rate stroke 0 jCCI ! 1 represents the mortality rate in the comparison cohort with comorbidity, Rate stroke 1 jCCI 0 represents the mortality rate in the stroke cohort without comorbidity, and Rate stroke0jCCI0 represents the mortality rate in the comparison cohort without comorbidity, namely the baseline risk.
Thereafter, we obtained the attributable fraction due to interaction as the proportion (%) of the mortality rate among stroke patients with comorbidity attributed to the interaction contrast [23] :
We stratified the analyses based on age subgroups (< 60 years and ≥ 60 years). To assess the robustness of our results with respect to potential stroke misclassification, we performed a sensitivity analysis restricted to stroke patients who underwent brain imaging during hospitalization and their matched counterparts. We also performed a sensitivity analysis restricted to the 2004-2012 index period when structural brain imaging was more widely available for stroke patients, providing a minimum of 8 years of outpatient history of comorbidities included in the DNPR.
S.K.S. conducted the analyses using SAS version 9.4 (SAS Inc., Cary, NC, USA). Table S1 provides definitions of all study variables. The conduct of the study was approved by the Danish Data Protection Agency (record number 1-16-02-1-08).
Results
Between 1995 and 2012, we identified 201 691 patients for inclusion in the stroke cohort with a median age of 73 years (interquartile range [IQR] , 62-81 years). For 83% of patients, stroke was the primary reason for inpatient admission. Comorbidity was identified in 36% of stroke patients. Of these, 17% had low comorbidity, 16% had moderate comorbidity and 3% had high comorbidity. The majority of patients in the stroke cohort were matched to five individuals in the general population. This resulted in a comparison cohort of 992 942 individuals with similar age, sex and comorbidity distributions ( Table 1) . We excluded 2% of stroke patients from the study for whom no match was available. Most of the excluded stroke patients were older than 80 years and had high comorbidity (Table S2) .
Mortality risks and standardized rates
During median follow-up of 5 years (IQR, 2.25-5.0 years), 5-year mortality was 48.0% (95% confidence interval [CI], 47.8-48.3%) in the stroke cohort and 31.6% (95% CI, 31.5-31.7%) in the comparison cohort. Fiveyear mortality (95% CI) was 41.1% (40.7-41.4%) after ischemic stroke and 54.2% (53.6-54.7%) after hemorrhagic stroke. By comorbidity level, 5-year mortality (95% CI) was 39.7% (39.4-39.9%) among stroke patients with no comorbidity, 57.0% (56.4-57.5%) among those with low comorbidity, 65.5% (65.0-66.0%) among those with moderate comorbidity and 79.5% (78.4-80.6%) among those with high comorbidity.
During the 30-day peak mortality after stroke (mortality risk = 15.5% [95% CI, 15.4-15.7%]), the mortality (95% CI) also increased with increasing level of comorbidity. Mortality was 12.7% (12.5-12.9%) among patients with no comorbidity, 18.3% (17.8-18.7%) among patients with low comorbidity, 21.1% (20.7-21.6%) among patients with moderate comorbidity and 28.1% (27.0-29.2%) among those with high comorbidity.
The standardized mortality rate was 187 per 1000 person-years in the stroke cohort and 90 per 1000 personyears in the comparison cohort (rate difference, 97 per 1000 person-years). In the first year of follow-up, both the period-specific standardized mortality rates and rate differences after stroke increased with higher comorbidity burden ( Table 2) .
Interaction between stroke and comorbidity
During the first year of follow-up, particularly in the initial 30-day period, interaction with comorbidity resulted in increased post-stroke mortality across all comorbidity levels, all individual comorbidities, all age groups, and among both ischemic and hemorrhagic stroke patients (Tables 2,3, Table S3 , Fig. 1 ). Among adults below age 60 years and among cancer patients, the interaction was seen for up to 5 years (Table S3 , Fig 2) .
Because of interaction, 30-day post-stroke mortality rates were increased at an excess of 47, 81 and 180 deaths per month for every 1000 patients with low, moderate and high comorbidity, respectively. This excess mortality as a result of interaction represented 23%, 34% and 51% of the total rate among stroke patients with low, moderate and high comorbidity, respectively (Table 2 ). This excess 30-day mortality as a result of interaction represented 26%, 27% and 44% of the total mortality rate among hemorrhagic stroke patients, and 33%, 44% and 59% of the total mortality rate among ischemic stroke patients (Table 3) . From 31 to 365 days after stroke, interaction was less substantial but still accounted for 5-32% of the mortality rates observed, depending on comorbidity level (Tables 2 and 3) .
The interaction contrasts were most notable among stroke patients with cancer, particularly hematological or metastatic cancer, followed by patients with moderate-tosevere liver or renal disease (Figs 1,2) . The notable interaction between hematological cancer and stroke affecting patient mortality was driven mostly by the hemorrhagic stroke subgroup (Table 3) . Interaction contrasts were least pronounced among stroke patients with cardiovascular comorbidity (Fig. 2) . 
Sensitivity analyses
The sensitivity analyses for the index period of 2004-2012 or for stroke patients who underwent brain imaging during hospitalization produced consistent results compared with the main analysis (Table S3 ).
Discussion
Comorbidity increased 1-year mortality after stroke beyond the combined expected effects of comorbidity and stroke acting alone. The excess mortality as a result of interaction was highest in the initial 30 days following stroke and among patients with hematological or metastatic cancer, followed by patients with moderate-to-severe renal or liver disease. The effect lasted up to 5 years after the stroke among cancer patients and among patients younger than 60 years.
Several previous studies have consistently shown either the same individual types or groups of comorbidities affecting mortality after hospital admission for stroke [2, 3, 6, 7, 24] . However, no study has shown how the effect of comorbidity on post-stroke mortality relates to the effect in the general population. Our work adds to existing knowledge by demonstrating that comorbidity resulted in increased post-stroke mortality significantly more than it resulted in increased mortality in the general population. We observed that interaction between stroke and comorbidity increased 1-year mortality regardless of stroke type, across all CCI comorbidity levels and across individual comorbidities. Vascular comorbidity such as myocardial infarction, diabetes and peripheral vascular disease had only limited impact on post-stroke mortality compared with other CCI comorbidities, notably cancer, but also moderate-to-severe renal or liver disease and dementia. Although the impact of comorbidity on increased patient mortality is viewed often as a feature of aging, we found that the effect of comorbidity was more pronounced among stroke patients below age 60 years. Several factors may explain our results. Patients with comorbidities generally have more severe strokes [7, 9] , thereby substantially affecting patient disability [8, 9] and mortality. Comorbidity and its associated polypharmacy [25] may affect post-stroke mortality by either affecting the provision of care, increasing the risk of complications [10, 11] or stroke recurrence [12] . The limited impact of most cardiovascular comorbidities compared with other CCI comorbidities could reflect in part the more effective treatments for cardiovascular disease in comparison with the other measured comorbidities. For example, bleeding disorders are common in renal and liver disease and in hematological cancers [26, 27] , and may preclude optimal care of the stroke patient [28] . Hypercoagulability is associated with higher inpatient stroke mortality and is a clinical feature of cancers, particularly among hematological malignancies and metastatic disease [24, 29] . Hypercoagulability may thus explain in part the interaction observed between stroke and these malignancies. Consistent with this finding, venous thromboembolism rates within 3 months after stroke are increased in patients with cancer more than expected based on either disease acting alone [10] .
Our interaction contrast results imply that up to 23% to 51% of all deaths among stroke patients with a low to high comorbidity burden might be postponed by fully effective interventions in the 30-day period after stroke. However, as CCI comorbidities most strongly affecting post-stroke mortality are also associated with reduced life expectancy, the impact of interventions tailored according to comorbidity would potentially yield a more modest survival benefit. For some comorbidities such as metastatic cancer, it may not be possible to use the best therapies otherwise available for stroke patients [24] , or the best available therapies may not result in similar improvements in outcome in comparison with patients with other comorbidities [30] . Therefore, the potential gain in survival will depend on the ability to improve stroke care among patients with different comorbidities. Finally, our results suggest that personalized interventions tailored to comorbidity may improve patient survival even among those who survive beyond the critical first 30 days after stroke admission.
This study had negligible selection bias owing to complete hospital registration of stroke and complete followup for death and migrations. We were thus able to address at the individual level the benefit that could be gained from tailoring stroke interventions according to a wide spectrum of major comorbidities over up to 5 years of follow-up. At the population level, highly prevalent comorbidities among stroke patients, such as cardiovascular diseases (compared with comorbidities with a lower incidence, such as leukemia and lymphoma), could result in a higher attributable fraction of mortality due to interaction with stroke. Nonetheless, our results reflected a slightly younger and less comorbid stroke population (98% of all stroke patients) for whom a matched individual in the general population could be found.
Potential misclassification of stroke probably did not affect our results, which were robust in analyses restricted to stroke patients undergoing structural brain imaging, and in analyses restricted to the 2004-2012 period when brain imaging was widely implemented in Denmark [17] . However, our study results were limited to comorbidities included in the CCI that led to hospital contacts within 10 years preceding the index date. Comorbidities not included in the CCI, as well as comorbidities diagnosed more than 10 years before the index date or in the general practice setting may have a different impact on post-stroke mortality. During this 10-year period, we have also not controlled for or assessed any potential effect of comorbidity with regard to the temporal proximity of diagnosis to the index date [21] . Moreover, the DNPR may have underrepresented less severe CCI comorbidities, particularly in the comparison cohort and before 1995. For these comorbidities, incompleteness could have yielded interaction contrast results above zero. Nevertheless, our interaction contrast findings for all CCI levels were consistent in the 2004 to 2012 index period, which included patients with at least an 8-year outpatient history of comorbidities in the DNPR.
In conclusion, comorbidity, notably cancer and advanced renal or liver disease, increased 1-year mortality after stroke beyond the combined effects expected from either disease acting alone. Continuing research efforts are warranted to better tailor interventions and assess the associated survival benefit among stroke patients with comorbidities. 
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